Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Enlivex Therapeutics Ltd logo
    ENLV

    Enlivex Therapeutics Ltd

    MaveScore 26 Low model confidence
    Last Price US$0.66 As of Jun 15, 2026
    Market Cap US$170.3m Company size context
    7D Performance -7.96% Past 7 days
    1Y Performance -29.62% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Dec 31, 2025

    167 days old

    Market price date

    Jun 15, 2026

    1 day old

    Coverage

    14/16

    2 missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 26 Low confidence

    Stored data quality

    Freshness and coverage checks

    Latest stored fundamentals and price inputs are recent enough for normal research review.

    14/16 Current stored snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    15/35 Weak

    Financial Strength

    Financial strength rewards durable profitability, margins, and positive free cash flow.

    0/25 Weak

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    10/15 Mixed

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    1/15 Weak

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    0/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength rewards durable profitability, margins, and positive free cash flow.
    • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    Enlivex Therapeutics Ltd Overview

    Industry: Biotechnology

    Sector: Healthcare

    Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

    Enlivex Therapeutics Ltd is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review Enlivex Therapeutics Ltd in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    News Image
    There is no doubt that Enlivex Therapeutics Ltd (ENLV) ticks all the boxes.
    6 minutes ago
    News Image
    Why Is Amentum Stock Rising Over 9% Premarket Today?
    27 minutes ago
    News Image
    Can La Tim Metal Industries Limited Deliver Relative Outperformance to Sector - Healthcare Stock Analysis & Go Beyond the Headlines With Analyst Picks
    3 hours ago

    Enlivex Therapeutics Ltd Competitors

    Enlivex Therapeutics Ltd operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    Enlivex Therapeutics Ltd

    US$0.66

    US$170.3m

    -7.96%

    -29.62%